Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • Alexza, Ferrer deal

    Alexza Pharmaceuticals Inc. (NASDAQ:ALXA), Mountain View, Calif. Grupo Ferrer Internacional S.A., Barcelona, Spain Business: Neurology The companies eliminated undisclosed milestone payments under a 2011 deal granting …

    Published on 11/17/2014
  • Aveo Pharmaceuticals, Ophthotech deal

    Aveo Pharmaceuticals Inc. (NASDAQ:AVEO), Cambridge, Mass. Ophthotech Corp. (NASDAQ:OPHT), New York, N.Y. Business: Ophthalmic Aveo granted Ophthotech an option to license exclusive ex-Asia development and …

    Published on 11/17/2014
  • BHV Pharma, Libbs deal

    BHV Pharma Inc., Research Triangle Park, N.C. Libbs Farmaceutica Ind., Sao Paulo, Brazil Business: Endocrine/Metabolic, Hepatic BHV granted Libbs exclusive rights in select Latin American countries, including Brazil, to…

    Published on 11/17/2014
  • Chembio, Integrated BioTherapeutics deal

    Chembio Diagnostics Inc. (NASDAQ:CEMI), Medford, N.Y. Integrated BioTherapeutics Inc., Gaithersburg, Md. Business: Diagnostic Chembio and Integrated BioTherapeutics partnered to develop point-of-care diagnostics for …

    Published on 11/17/2014
  • Clinuvel, Biotech Lab Singapore deal

    Clinuvel Pharmaceuticals Ltd. (ASX:CUV;Pink:CLVLY), Melbourne, Australia Biotech Lab Singapore Ltd., Business: Dermatology, Endocrine/Metabolic Clinuvel and Biotech Lab Singapore formed a JV to develop pediatric …

    Published on 11/17/2014
  • CTI BioPharma, Servier deal

    CTI BioPharma Corp. (NASDAQ:CTIC;Milan:CTIC), Seattle, Wash. Servier, Neuilly-sur-Seine, France Business: Cancer CTI granted Servier exclusive rights to develop and commercialize Pixuvri pixantrone outside of the U.S. …

    Published on 11/17/2014
  • Evotec, Jain Foundation deal

    Evotec AG (Xetra:EVT), Hamburg, Germany Jain Foundation Inc., Seattle, Wash. Business: Musculoskeletal Evotec and Jain extended and expanded their 2012 deal to develop a cell-based high throughput screening assay using …

    Published on 11/17/2014
  • Five Prime, GlaxoSmithKline deal

    Five Prime Therapeutics Inc. (NASDAQ:FPRX), South San Francisco, Calif. GlaxoSmithKline plc (LSE:GSK;NYSE:GSK), London, U.K. Business: Pulmonary, Inflammation The companies added two programs targeting chronic …

    Published on 11/17/2014
  • Geron, J&J deal

    Geron Corp. (NASDAQ:GERN), Menlo Park, Calif. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Cancer, Hematology Geron granted Johnson & Johnson's Janssen Biotech Inc. unit exclusive, worldwide rights to …

    Published on 11/17/2014
  • Huya, TIPR deal

    Huya Bioscience International LLC, San Diego, Calif. Tianjin Institute of Pharmaceutical Research, Tianjin, China Business: Pharmaceuticals Huya and Tianjin Institute of Pharmaceutical Research formed a JV to develop …

    Published on 11/17/2014
  • Intarcia, Servier deal

    Intarcia Therapeutics Inc., Boston, Mass. Servier, Neuilly-sur-Seine, France Business: Endocrine/Metabolic Intarcia granted Servier exclusive rights to develop and commercialize ITCA 650 outside of the U.S. and Japan. …

    Published on 11/17/2014
  • Isis Pharmaceuticals, AstraZeneca deal

    Isis Pharmaceuticals Inc. (NASDAQ:ISIS), Carlsbad, Calif. AstraZeneca plc (LSE:AZN;NYSE:AZN), London, U.K. Business: Drug delivery The companies partnered to develop new targeted delivery methods for antisense …

    Published on 11/17/2014
  • NuView, Otsuka Pharmaceutical deal

    NuView Life Sciences Inc., Park City, Utah Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan Business: Diagnostic NuView granted Otsuka exclusive, worldwide rights to develop and commercialize NuView's genomic-based …

    Published on 11/17/2014
  • Pharmacyclics, Roche deal

    Pharmacyclics Inc. (NASDAQ:PCYC), Sunnyvale, Calif. Roche (SIX:ROG;OTCQX:RHHBY), Basel, Switzerland Business: Cancer The companies partnered to evaluate Imbruvica ibrutinib in combination with Gazyva obinutuzumab in a …

    Published on 11/17/2014
  • Presidio, Ascletis deal

    Presidio Pharmaceuticals Inc., San Francisco, Calif. Ascletis Pharmaceuticals Co. Ltd., Hangzhou, China Business: Infectious Presidio granted Ascletis exclusive development and commercialization rights to PPI-668 in …

    Published on 11/17/2014
  • Aciex Therapeutics, Nicox deal

    Aciex Therapeutics Inc., Boston, Mass. Nicox S.A. (Euronext:COX), Sophia Antipolis, France Business: Ophthalmic Nicox completed its acquisition of Aciex (see BioCentury, July 14).

    Published on 11/10/2014
  • Alopexx Pharmaceuticals, sanofi-aventis deal

    Alopexx Pharmaceuticals LLC, Concord, Mass. sanofi-aventis Group (Euronext:SAN;NYSE:SNY), Paris, France Business: Infectious Sanofi (formerly sanofi-aventis Group) disclosed in its 3Q14 earnings that it and Alopexx …

    Published on 11/10/2014
  • AstraZeneca, Aegerion deal

    AstraZeneca plc (LSE:AZN;NYSE:AZN), London, U.K. Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR), Cambridge, Mass. Business: Endocrine/Metabolic AstraZeneca will divest worldwide rights to develop and commercialize Myalept …

    Published on 11/10/2014
  • Bind Therapeutics, Merck deal

    Bind Therapeutics Inc. (NASDAQ:BIND), Cambridge, Mass. Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Business: Cancer The companies partnered to discover and develop nanomedicines using Bind's Medicinal …

    Published on 11/10/2014
  • Covance, LabCorp deal

    Covance Inc. (NYSE:CVD), Princeton, N.J. Laboratory Corp. of America Holdings (NYSE:LH), Burlington, N.C. Business: Diagnostic Diagnostic company LabCorp will acquire CRO Covance for $105.12 per share, or $5.9 billion …

    Published on 11/10/2014
  • Definiens, AstraZeneca deal

    Definiens AG, Munich, Germany AstraZeneca plc (LSE:AZN;NYSE:AZN), London, U.K. Business: Diagnostic AstraZeneca's MedImmune LLC unit will acquire Definiens for $150 million plus undisclosed milestone payments. MedImmune…

    Published on 11/10/2014
  • Dnavec, Sumitomo Dainippon deal

    Dnavec Corp., Tsukuba, Japan Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506), Osaka, Japan Business: Neurology, Gene/Cell therapy, Ophthalmic The Dnavec Corp. subsidiary of I'rom granted Sumitomo Dainippon a license to …

    Published on 11/10/2014
  • Doliage, Nicox deal

    Doliage, Paris, France Nicox S.A. (Euronext:COX), Sophia Antipolis, France Business: Ophthalmic Nicox acquired French ophthalmic play Doliage for EUR5 million ($6.2 million) in newly issued Nicox shares. Nicox said the …

    Published on 11/10/2014
  • Eli Lilly, Denovo Biopharma deal

    Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Denovo Biopharma LLC, San Diego, Calif. Business: Cancer Denovo acquired enzastaurin (DB102) from Eli Lilly. In 2013, Lilly discontinued development of enzastaurin (…

    Published on 11/10/2014
  • Eli Lilly, Virbac Group deal

    Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Virbac Group (Euronext:VIRP), Carros, France Business: Veterinary Eli Lilly will divest to Virbac major veterinary products marketed in the U.S. by the Novartis Animal …

    Published on 11/10/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993